Quell is a wearable intensive nerve stimulation device to help people manage chronic pain. The device is activated by a simple button click, and taps into the body’s natural pain relief response to block pain signals and deliver widespread relief.
Quell has been cleared by the U.S. Food and Drug Administration (FDA) to be used during the day and at night while sleeping. The device can be started, stopped, and adjusted via the optional Quell Relief app, and also offers sleep tracking.
“We have seen both clinical data and positive reviews that suggest that Quell may be beneficial in reducing pain and improving the quality of life in people who suffer from fibromyalgia,” said Shai N. Gozani, MD, PhD, president and CEO of NeuroMetrix, in a press release. “This clinical evaluation will provide additional evidence for fibromyalgia patients and their healthcare providers who are considering Quell as a pain relief option.”
“Clinical research on innovative therapies is an integral part of what we do,” said Kunal Gogna, MD, from the Synovation Medical Group. “We are excited to test the Quell technology and potentially add it to our multidisciplinary approach to pain management.”
Led by Gogna and Mauro Zappaterra, MD, PhD, director of Clinical Research, the Synovation Medical Group supports the use of medical devices as alternatives to medication for the treatment of various chronic pain ailments.
NeuroMetrix and the Scripps Translational Science Institute are currently testing the effects of Quell on opioid reduction and pain relief in patients with cancer. This single site, double-blinded, and placebo-controlled clinical trial (NCT02809846) is enrolling about 40 participants by invitation only.
Fibromyalgia is a chronic condition that characteristically causes pain all over the body, including muscle and joint pain, as well as fatigue and other symptoms. According to the Centers of Disease Control and Prevention (CDC), the prevalence of fibromyalgia is about 2%, affecting an estimated 5 million adults in the U.S.